07:35 AM EST, 01/02/2025 (MT Newswires) -- ANI Pharmaceuticals ( ANIP ) said Thursday it has launched its prucalopride tablets, the generic version of Motegrity, after receiving final approval from the US Food and Drug Administration.

The FDA granted the drug a competitive generic therapy designation, providing ANI with 180 days of market exclusivity, the company said.

Motegrity, or prucalopride, is intended to treat a type of constipation called chronic idiopathic constipation.

Shares of ANI gained more than 1% in recent premarket activity Thursday.

Price: 56.10, Change: +0.82, Percent Change: +1.48